Success Metrics

Clinical Success Rate

50.0%

Based on 2 completed trials

Completion Rate

50%(2/4)

Active Trials

0(0%)

Results Posted

200%(4 trials)

Terminated

2(40%)

Phase Distribution

Ph phase_2

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

5(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(2)

Terminated(2)

Detailed Status

Completed2

Terminated2

Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 2

Trials by Phase

Phase 25 (100.0%)

Trials by Status

enrolling_by_invitation120%

completed240%

terminated240%

Recent Activity

0 active trials

Showing 5 of 5

enrolling_by_invitationphase_2

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

NCT06674577

terminatedphase_2

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

NCT02070978

completedphase_2

Clinical Trials (5)

Showing 5 of 5 trials

NCT06674577Phase 2

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Enrolling By Invitation

NCT02070978Phase 2

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

Terminated

NCT01972568Phase 2

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

Completed

NCT00853762Phase 2

Atacicept in Multiple Sclerosis Extension Study, Phase II

Terminated

NCT00624338Phase 2

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5